Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2025

Summary of Financial Information for Segment

The following table represents selected financial information for our segment for the years ended December 31, 2025, 2024 and 2023, in thousands:


	Year Ended December 31,
	2025		2024		2023
Collaboration revenue	$	—	$	—	$	7,000
Internal costs
Total salary / benefits	21,800		21,228		30,105
External costs by program
Zetomipzomib	15,855		36,652		40,513
KZR-261	839		5,940		6,428
Other protein secretion discovery programs	33		289		5,604
General and administrative	9,523		10,888		13,663
Other segment items (1)	11,057		15,608		22,111
Total operating expenses	$	59,107	$	90,605	$	118,424
Loss from operations	(59,107)		(90,605)		(111,424)
Interest income	4,444		8,462		11,104
Other expenses	(1,370)		(1,593)		(1,550)
Consolidated segment net loss	$	(56,033)	$	(83,736)	$	(101,870)

(1) Other segment items include stock-based compensation expense, depreciation and amortization, loss on disposal of property and equipment, impairment loss of property and equipment, and in 2024 and 2023, impairment loss of right-of-use asset.